{"id":"W3210624555","doi":"10.1002/ajh.26400","title":"Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase <scp>IB</scp>/<scp>II</scp> study","year":2021,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Internal medicine; Obinutuzumab; Tolerability; Rituximab; Oncology; Bendamustine; Antibody-drug conjugate; Lymphoma; Phases of clinical research; Follicular lymphoma; Refractory (planetary science); Gastroenterology; Chemotherapy; Immunology; Adverse effect; Monoclonal antibody; Antibody; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001846336,0.0009060981,0.001748725,0.0003081544,0.000307259,0.001553088,0.0007654951,0.001039445,0.00221988],"category_scores_gemma":[0.001208065,0.0004255926,0.00127425,0.0004126164,0.0006987266,0.0008720633,0.0001883454,0.001912617,0.0006188425],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001142295,"about_ca_system_score_gemma":0.001178445,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007202276,"about_ca_topic_score_gemma":0.001053937,"domain_scores_codex":[0.9994808,0.0002181886,0.00003803882,0.00009166905,0.00009366329,0.00007775045],"domain_scores_gemma":[0.9988973,0.0002150133,0.000272622,0.000121552,0.0001141505,0.0003793127],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7170617,0.04280441,0.009854493,0.001480014,0.002684524,0.0004212532,0.0003919983,0.002577228,0.04425538,0.0004256238,0.004674337,0.173369],"study_design_scores_gemma":[0.4197946,0.529845,0.02736917,0.0001458652,0.001805065,0.0008233035,0.0001014362,0.002221708,0.007818925,0.0005116468,0.009506529,0.00005677904],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986264,0.007859578,0.0007157368,0.0003158326,0.0001607087,0.00125311,0.001332767,0.00006842559,0.002029872],"genre_scores_gemma":[0.991557,0.003446804,0.0005609371,0.000651433,0.0001865248,0.0005916567,0.00157109,0.00002789625,0.00140663],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00221988,"threshold_uncertainty_score":0.009764493,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01415377187334877,"score_gpt":0.2901016079793007,"score_spread":0.275947836105952,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}